Sign In
Buy REPL
$9.98
+1.11 (+12.51%)
At Close: Jun 03, 2026
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman
07:50pm, Wednesday, 06'th Aug 2025
SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al.
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors a
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities law
REPL DEADLINE: Replimune Group Investors Should Contact Block & Leviton By September 22nd To Join Securities Fraud Lawsuit
12:08pm, Tuesday, 05'th Aug 2025
Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Replimune Group (Nasdaq: REPL). Investors should contact the firm.
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:42am, Tuesday, 05'th Aug 2025
LOS ANGELES , Aug. 5, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune"
NEW YORK , Aug. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024
NEW YORK , Aug. 4, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased t
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchase
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman
03:53pm, Monday, 04'th Aug 2025
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al.
Why Is Replimune Stock Trading Lower On Monday?
12:43pm, Monday, 04'th Aug 2025
On Monday, Replimune Group Inc. REPL is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage.
ATLANTA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges th
REPL LAWSUIT ALERT: The Gross Law Firm Notifies Replimune Group, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
08:45am, Monday, 04'th Aug 2025
NEW YORK , Aug. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the cla
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm
03:48am, Monday, 04'th Aug 2025
NEW YORK , Aug. 4, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Replimune Group,
